OGXI Key Stats
- Nasdaq stocks posting largest percentage increases May 13
- ONCOGENEX PHARMACEUTICALS, INC. Financials May 10
- OncoGenex Loss Lower than Expected May 6
- OncoGenex Loss Lower than Expected - Analyst Blog Zacks May 6
- OncoGenex Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcr... May 3
- OncoGenex Pharmaceuticals Provides Clinical Development Program Overview and Rep... May 2
- OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview a... May 2
- ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Fi... May 2
- Q1 2013 Oncogenex Pharmaceuticals, Inc. Earnings Release - After Market Close May 2
- OncoGenex Pharmaceuticals Becomes Oversold (OGXI) May 1
OGXI Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). OncoGenex Pharmaceuticals is down 17.99% over the last year vs S&P 500 Total Return up 31.59%, Acorda Therapeutics up 48.48%, and Merus Labs International down 65.00%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for OGXI
Pro Report PDF for OGXI
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download OGXI Pro Report PDF
Pro Strategies Featuring OGXI
Did OncoGenex Pharmaceuticals make it into our Pro Portfolio Strategies?